表紙
市場調査レポート

痛風の予測:主要15市場

Gout Forecast in 15 Major Markets 2015-2025

発行 Black Swan Analysis 商品コード 339838
出版日 ページ情報 英文 74 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
痛風の予測:主要15市場 Gout Forecast in 15 Major Markets 2015-2025
出版日: 2015年09月01日 ページ情報: 英文 74 Pages
担当者のコメント
国別の有病率などデータ中心にまとめているレポートです。
概要

痛風は、関節内に尿酸が蓄積することによって引き起こされます。

当レポートでは、主要15市場 (米国、フランス、ドイツ、イタリア、スペイン、英国、ブラジル、日本、カナダ、オーストラリア、オランダ、チェコ共和国、ギリシャ、インド、メキシコ) における痛風の現在の患者数 (性別、年齢コホート別) について調査分析し、現在の有病率のほか、疾患の概要、危険因子、疾患の診断と予後、主な症状や合併症など、体系的な情報を提供しています。

図表

イントロダクション

病因

危険因子と予防

疾患の診断

変異:地域/民族別

疾患予後と臨床経過

疾患に関連する主な合併症/特徴

患者数を定量化する手法

  • 追加データ

痛風の有病率トップライン

過去12ヶ月間に炎症経験のある痛風患者の特徴

  • 過去12ヶ月間の炎症の頻度
  • 炎症中の痛風患者の関節障害
  • 痛風患者の腎機能と特徴

最初の発現時の痛風患者の特徴

痛風に関連する合併症

結節性痛風

略語

関連出版

患者ベースのオンラインデータベース

患者ベースの製品

価格のオンラインデータ・プラットフォーム

参考文献

付録

目次
Product Code: GOUT0010915

Gout is caused by the build up of uric acid in the joints due to the body producing too much or excreting too little in the urine, and develops into sodium urate crystals. The formation of these crystals causes pain and inflammation around bone joints. The majority of Gout attacks involve the first metatarsophalangeal joint (FMJ) which is the "big toe" (also known as podagra). Gout can also occur in other joints of the body such as the spine, other parts of the foot, hips or shoulders and hands.

This report provides the current prevalent population for Gout across 15 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, Canada, Australia, Netherlands, Czech Republic, Greece, India and Mexico) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the frequency of Gout flares, joint involvement, kidney function and presence of tophi in Gout. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Gout have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Gout include:

  • Obesity and weight gain
  • Kidney stones, renal cysts and renal failure
  • Coronary artery disease, Chronic Heart Failure
  • Hypertension
  • Dyslipidaemia
  • Diabetes mellitus
  • Metabolic syndrome
  • Hyperuricaemia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Gout's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Gout and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Gout's prevalent population.
  • Identify sub-populations within Gout which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Gout patients.

Coverage

US, UK, FR, DE, IT, ES, JP, BR, IN

Table of Contents

List of Tables and Figures

Introduction

Cause of the Disease

Risk Factors & Prevention

Diagnosis of the Disease

Variation by Geography/Ethnicity

Disease Prognosis &Clinical Course

Key Co-morbid Conditions /Features Associated with the Disease

Methodology for Quantification of Patient Numbers

  • Additional data available on request

Top-Line Prevalence for Gout

Features of Gout Patients Experiencing Flare in Past 12 Months

  • Frequency of Flare in past 12 months
  • Joint Involvement in Gout patients during Flare
  • Kidney Function and Features in patients with Gout

Features of Gout Patients at Initial Presentation

Associated Co-morbid Conditions of Gout

Tophaceous Gout

Abbreviations used in the Report

Other Black Swan Analysis Publications

Black Swan Analysis Online Patient-Based Databases

Patient-Based Offering

Online Pricing Data and Platforms

References

Appendix

List of Figures

  • ACR criteria for diagnosis of Gout
  • ROME criteria for diagnosis of Gout
  • New York criteria for diagnosis of Gout

List of Tables

  • Prevalence of Gout, total (000s)
  • Prevalence of Gout, males (000s)
  • Prevalence of Gout, females (000s)
  • Gout patients with at least one flare in the past 12 months, total (000s)
  • Number of flares in past 12 months, total (000s)
  • Location of affected joint in patients with Gout flare, total (000s)
  • The extent of joint involvement in patients during Gout flare, total (000s)
  • eGFR status of patients with Gout, total (000s)
  • Prevalence of Renal Cysts in patients with Gout, total (000s)
  • Prevalence of Nephrolithiasis in patients with Gout, total (000s)
  • Estimated annual incidence of Gout, total (000s)
  • Body Mass Index of patients with Gout at initial presentation, total (000s)
  • Gout patients with a family history of Gout, total (000s)
  • Uric acid level at presentation for patients with Gout, total (000s)
  • Diabetes Mellitus in patients with Gout, total (000s)
  • Dyslipidaemia in patients with Gout, total (000s)
  • Prevalence of Hypertension in patients with Gout, total (000s)
  • Hyperuricaemia in patients with Gout, total (000s)
  • Metabolic Syndrome in patients with Gout, total (000s)
  • Osteoarthritis in patients with Gout, total (000s)
  • Peripheral Artery Disease in patients with Gout, total (000s)
  • Presence of tophi in patients with Gout, total (000s)
  • Patients with tophi by number present, total (000s)
  • Abbreviations and Acronyms used in the report
  • USA Prevalence of Gout by 5-yr age cohort, males (000s)
  • USA Prevalence of Gout by 5-yr age cohort, females (000s)
  • France Prevalence of Gout by 5-yr age cohort, males (000s)
  • France Prevalence of Gout by 5-yr age cohort, females (000s)
  • Germany Prevalence of Gout by 5-yr age cohort, males (000s)
  • Germany Prevalence of Gout by 5-yr age cohort, females (000s)
  • Italy Prevalence of Gout by 5-yr age cohort, males (000s)
  • Italy Prevalence of Gout by 5-yr age cohort, females (000s)
  • Spain Prevalence of Gout by 5-yr age cohort, males (000s)
  • Spain Prevalence of Gout by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of Gout by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of Gout by 5-yr age cohort, females (000s)
  • Brazil Prevalence of Gout by 5-yr age cohort, males (000s)
  • Brazil Prevalence of Gout by 5-yr age cohort, females (000s)
  • Japan Prevalence of Gout by 5-yr age cohort, males (000s)
  • Japan Prevalence of Gout by 5-yr age cohort, females (000s)
  • Canada Prevalence of Gout by 5-yr age cohort, males (000s)
  • Canada Prevalence of Gout by 5-yr age cohort, females (000s)
  • Australia Prevalence of Gout by 5-yr age cohort, males (000s)
  • Australia Prevalence of Gout by 5-yr age cohort, females (000s)
  • Netherlands Prevalence of Gout by 5-yr age cohort, males (000s)
  • Netherlands Prevalence of Gout by 5-yr age cohort, females (000s)
  • Czech Republic Prevalence of Gout by 5-yr age cohort, males (000s)
  • Czech Republic Prevalence of Gout by 5-yr age cohort, females (000s)
  • Greece Prevalence of Gout by 5-yr age cohort, males (000s)
  • Greece Prevalence of Gout by 5-yr age cohort, females (000s)
Back to Top